MoonLake Immunotherapeutics
MLTX
$16.47
-$0.03-0.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -49.67% | -77.04% | -91.13% | -160.62% | -221.44% |
| Total Depreciation and Amortization | 76.40% | 114.84% | 88.88% | 61.36% | 77.52% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 337.57% | 292.57% | 85.70% | 26.41% | 72.34% |
| Change in Net Operating Assets | 360.57% | 790.75% | 625.32% | 353.43% | 120.74% |
| Cash from Operations | -35.31% | -60.36% | -68.12% | -130.79% | -158.28% |
| Capital Expenditure | 100.00% | 100.00% | 93.27% | 66.43% | 30.93% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 5.59% | 222.16% | 199.00% | 44.83% | 132.15% |
| Cash from Investing | 6.24% | 221.82% | 198.73% | 46.02% | 131.86% |
| Total Debt Issued | -66.49% | -66.49% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 91,617.54% | 23,014.62% | 38.26% | -99.13% | -99.59% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | 102.13% |
| Cash from Financing | 360.33% | 40.93% | 184.53% | -7.32% | -7.48% |
| Foreign Exchange rate Adjustments | -146.22% | 12,000.00% | 766.41% | 723.43% | 1,320.47% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 574.17% | 114.41% | 156.91% | -143.35% | 77.29% |